BRPI0822909A2 - Sal de glicinato de metformina para o controle da glicose sanguínea - Google Patents

Sal de glicinato de metformina para o controle da glicose sanguínea

Info

Publication number
BRPI0822909A2
BRPI0822909A2 BRPI0822909-0A BRPI0822909A BRPI0822909A2 BR PI0822909 A2 BRPI0822909 A2 BR PI0822909A2 BR PI0822909 A BRPI0822909 A BR PI0822909A BR PI0822909 A2 BRPI0822909 A2 BR PI0822909A2
Authority
BR
Brazil
Prior art keywords
blood glucose
glucose control
glycinate salt
metformin glycinate
metformin
Prior art date
Application number
BRPI0822909-0A
Other languages
English (en)
Inventor
Jose Manuel Francisco Lara Ochoa
Original Assignee
Silanes Sa De Cv Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40383805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0822909(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Silanes Sa De Cv Lab filed Critical Silanes Sa De Cv Lab
Publication of BRPI0822909A2 publication Critical patent/BRPI0822909A2/pt
Publication of BRPI0822909B1 publication Critical patent/BRPI0822909B1/pt
Publication of BRPI0822909B8 publication Critical patent/BRPI0822909B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
BRPI0822909A 2008-06-26 2008-06-26 sal de glicinato de metformina para o controle da glicose sanguínea BRPI0822909B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/002665 WO2009144527A1 (en) 2008-06-26 2008-06-26 A new metformin glycinate salt for blood glucose control

Publications (3)

Publication Number Publication Date
BRPI0822909A2 true BRPI0822909A2 (pt) 2015-06-30
BRPI0822909B1 BRPI0822909B1 (pt) 2019-11-12
BRPI0822909B8 BRPI0822909B8 (pt) 2021-05-25

Family

ID=40383805

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0822909A BRPI0822909B8 (pt) 2008-06-26 2008-06-26 sal de glicinato de metformina para o controle da glicose sanguínea

Country Status (26)

Country Link
US (2) US8703183B2 (pt)
EP (1) EP2303838B1 (pt)
JP (1) JP5551691B2 (pt)
KR (1) KR101522066B1 (pt)
CN (1) CN102159539B (pt)
AR (1) AR074159A1 (pt)
AU (1) AU2008357111B2 (pt)
BR (1) BRPI0822909B8 (pt)
CA (1) CA2729035C (pt)
CL (1) CL2009001484A1 (pt)
CY (1) CY1115098T1 (pt)
DK (1) DK2303838T3 (pt)
EC (1) ECSP10010719A (pt)
ES (1) ES2450148T3 (pt)
HR (1) HRP20140194T1 (pt)
JO (1) JO2884B1 (pt)
MA (1) MA32418B1 (pt)
MX (1) MX2011000135A (pt)
NI (1) NI201000234A (pt)
PE (1) PE20100257A1 (pt)
PL (1) PL2303838T3 (pt)
PT (1) PT2303838E (pt)
SI (1) SI2303838T1 (pt)
TN (2) TN2010000607A1 (pt)
UY (1) UY31945A (pt)
WO (1) WO2009144527A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011000135A (es) 2008-06-26 2011-02-25 Silanes Sa De Cv Lab Una nueva sal de glicinato de metformina para el control de la glucosa en sangre.
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
CN103263405B (zh) * 2013-05-08 2015-04-22 南京医科大学 用于治疗糖尿病的药物组合物及其应用
US9815777B2 (en) 2013-09-22 2017-11-14 Jiva Pharma, Inc. Metformin salts to treat Type2 diabetes
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
WO2015171516A1 (en) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
WO2015183794A1 (en) * 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
CN107074884A (zh) 2014-06-18 2017-08-18 西蒂斯制药有限责任公司 活性剂的矿物质氨基酸复合物
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
AU2015339576B2 (en) 2014-10-27 2020-02-06 Glytec, Llc Subcutaneous outpatient management
CN105030745A (zh) * 2015-07-08 2015-11-11 南京医科大学 甘氨酸和二甲双胍的酰胺化产物在制备治疗糖尿病药物中的应用
AU2016308953B2 (en) 2015-08-20 2020-09-10 Glytec, Llc Diabetes management therapy advisor
CA3026264A1 (en) 2016-06-03 2017-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
BR112019006401A2 (pt) * 2016-09-30 2019-06-25 Laboratorios Silanes S A De C V glicinato de metformina, composições farmacêuticas que compreendem o mesmo e métodos de uso do mesmo
US11510886B2 (en) 2016-09-30 2022-11-29 Laboratorios Silanes, S.A. De C.V. Metformin amino acid compounds and methods of using the same
CN113105367B (zh) * 2021-03-30 2022-08-02 广州大学 一类二甲双胍盐及其制备方法和应用
CN114349665B (zh) * 2021-11-30 2023-06-09 潍坊博创国际生物医药研究院 二甲双胍焦谷氨酸晶体及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE568513A (pt)
FR2037002A1 (en) 1969-04-30 1970-12-31 Roques Bernard N-substd biguanide pamoic acid salts prepn
DE1967138A1 (de) 1969-07-17 1977-11-10 Christian Brunnengraeber Chem Therapeutisches mittel
AT325632B (de) 1973-06-01 1975-10-27 Hurka Wilhelm Verfahren zur herstellung von nicotinsauren salzen von derivaten des biguanids
FR2243684B1 (pt) 1973-09-19 1977-01-28 Semb
CH602612A5 (pt) 1974-10-11 1978-07-31 Hoffmann La Roche
FR2320735A1 (fr) 1975-08-12 1977-03-11 Dabis Georges Composition anti-cellulite
JPS57179494A (en) 1981-04-30 1982-11-05 Mitsubishi Plastics Ind Method of closing through hole of pipe, circumferential wall thereof has through hole in pipe axial direction
FR2585572B3 (fr) 1985-07-31 1987-12-31 Hugelin Andre Nouvelles compositions pharmaceutiques a base d'un sel de l'acide p. chlorophenoxyacetique destinees au traitement des neuropathies et assurant la regeneration nerveuse
DE793646T1 (de) * 1994-11-23 1999-12-30 Pharmacia & Upjohn Co., Kalamazoo Carboxylierte aminoguanidine zum behandlung von insulin-unabhängigem diabetes mellitus
WO1999029314A1 (en) 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Novel salts of metformin and method
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
AU2003211131A1 (en) * 2002-02-14 2003-09-04 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
US7181457B2 (en) * 2003-05-28 2007-02-20 Pervasive Software, Inc. System and method for utilizing compression in database caches to facilitate access to database information
EP1680083A1 (en) 2003-10-31 2006-07-19 ALZA Corporation Compositions and dosage forms for ehnanced absorption of iron
WO2005065675A1 (en) * 2004-01-07 2005-07-21 Premacs International Pty. Ltd. Method of treatment
EP2242489A1 (en) * 2005-02-15 2010-10-27 Jallal Messadek Combination therapeutic compositions and method of use
ATE540690T1 (de) * 2005-04-27 2012-01-15 Jallal Messadek Insulinkombinationen
WO2007149313A1 (en) * 2006-06-16 2007-12-27 Indigene Pharmaceuticals Inc. Metformin r-(+) lipoate as an antidiabetic agent for control of diabetic hyperglycemia and diabetic complications
NZ556735A (en) * 2007-07-24 2009-03-31 Vector Ltd Securing devices and equipotential bonding system
MX2011000135A (es) 2008-06-26 2011-02-25 Silanes Sa De Cv Lab Una nueva sal de glicinato de metformina para el control de la glucosa en sangre.

Also Published As

Publication number Publication date
JO2884B1 (en) 2015-03-15
US20110171142A1 (en) 2011-07-14
WO2009144527A1 (en) 2009-12-03
KR20110042165A (ko) 2011-04-25
JP5551691B2 (ja) 2014-07-16
MA32418B1 (fr) 2011-06-01
CA2729035C (en) 2015-10-20
DK2303838T3 (en) 2014-03-03
UY31945A (es) 2010-01-05
AU2008357111B2 (en) 2013-05-09
CA2729035A1 (en) 2009-12-03
CL2009001484A1 (es) 2009-12-04
CN102159539A (zh) 2011-08-17
ES2450148T3 (es) 2014-03-24
AU2008357111A1 (en) 2009-12-03
ECSP10010719A (es) 2011-01-31
EP2303838B1 (en) 2013-12-04
TN2010000607A1 (en) 2012-05-24
EP2303838A1 (en) 2011-04-06
AR074159A1 (es) 2010-12-29
MX2011000135A (es) 2011-02-25
SI2303838T1 (sl) 2014-07-31
CY1115098T1 (el) 2016-12-14
PT2303838E (pt) 2014-03-10
US8703183B2 (en) 2014-04-22
JP2011525900A (ja) 2011-09-29
BRPI0822909B1 (pt) 2019-11-12
HRP20140194T1 (hr) 2014-06-20
PL2303838T3 (pl) 2014-07-31
NI201000234A (es) 2012-03-19
PE20100257A1 (es) 2010-04-10
BRPI0822909B8 (pt) 2021-05-25
USRE46496E1 (en) 2017-08-01
TN2010000604A1 (en) 2012-05-24
CN102159539B (zh) 2014-04-16
KR101522066B1 (ko) 2015-05-20

Similar Documents

Publication Publication Date Title
BRPI0822909A2 (pt) Sal de glicinato de metformina para o controle da glicose sanguínea
BRPI0910282A2 (pt) Composto oxadiazo-antraceno para o tratamento de diabetes
BRPI0912380A2 (pt) válvula para controle de sangue rotacionalmente ativada
BRPI0918038A2 (pt) Processos para preparar um composto e um sal, e, composto
BRPI0908874A2 (pt) mecanismo de posicionamento de um leito
BRPI0722082A2 (pt) Ligantes para imagiologia da inervação cardíaca
BRPI0817110A2 (pt) Aparelho de controle para veículo
BRPI0912390A2 (pt) controle de sangue por botão de pressão
BRPI0918324A2 (pt) máscara de dormir, método para fornecer terapia de luz a um indivíduo, máscara configurada para fornecer terapia de luz a um indivíduo
BRPI0912729A2 (pt) válvula de controle do sangue por compressão radial
BRPI1006144A2 (pt) tratamento para diabetes em pacientes com controle glicêmico inadequado, não obstante terapia com metformina, compreendendo um inibidor de dpp-iv
BRPI1008836A2 (pt) dispositivo e método médicos para proporcionar informações de controle glicêmico
BRPI0821361A2 (pt) Derivados de aminobenzamida como agentes úteis para controle de parasitas animais
BRPI0716134A2 (pt) tratamento de combinaÇço para diabetes mellitus
BRPI0922444A2 (pt) mecanismo de controle da seção curvada do endoscópio
DE112012001009T8 (de) Konzentrischer Nockenwellenversteller-Torsionsantriebsmechanismus
BR112012000502A2 (pt) terapia de combinação para o tratamento de diabetes
DK2291368T3 (da) Substitueret gamma-lactam som terapeutisk middel
DK2108260T3 (da) Sammensætning med biocid aktivitet til vandige præparater
BRPI1016243A2 (pt) agentes químicos e biológicos para o controle de moluscos.
DK2011796T3 (da) Neurogenese-inducer eller terapeutisk middel mod neuropati omfattende alkyletherderivat eller salt deraf
BRPI0815552A2 (pt) Aparelho de controle para unidade de acionamento de veículo
BRPI0620396A2 (pt) médoto para o controle de ervas daninhas aquáticas
BRPI1014363A2 (pt) braçadeiras para controle de insetos
BRPI0910059A2 (pt) Composição sólida para controle de praga

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF